(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 18.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Acadia Pharmaceuticals's revenue in 2024 is $726,437,000.On average, 9 Wall Street analysts forecast ACAD's revenue for 2024 to be $158,881,927,753, with the lowest ACAD revenue forecast at $154,707,111,726, and the highest ACAD revenue forecast at $161,663,600,571. On average, 9 Wall Street analysts forecast ACAD's revenue for 2025 to be $175,988,342,292, with the lowest ACAD revenue forecast at $163,618,120,353, and the highest ACAD revenue forecast at $192,700,293,810.
In 2026, ACAD is forecast to generate $202,657,107,280 in revenue, with the lowest revenue forecast at $173,667,535,419 and the highest revenue forecast at $258,196,973,407.